Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma

The purpose of the present study was to evaluate the potency of the proteasome inhibitor bortezomib ± gemcitabine in vitro and in vivo in pancreatic carcinoma. It could be shown that bortezomib induced apoptosis and inhibited proliferation of pancreatic carcinoma very efficiently in vitro. In contrast, in an orthotopic pancreatic adenocarcinoma mouse model, gemcitabine treatment inhibited tumor growth, whereas bortezomib promoted it. Bortezomib-treated animals showed significantly higher tumor burden compared with gemcitabine-treated and control animals, although bortezomib was locally active and induced a decrease of proteasome activity, which was most pronounced following the simultaneous administration of gemcitabine. Also, tumor progression was not caused by immunosuppression as a result of proteasome inhibition. Interestingly, anti-CD31 staining of tumors showed that angiogenesis was significantly increased in the tumors of bortezomib-treated mice compared with the tumors of control animals. In addition, bortezomib resulted an increase of pericytes, vascular endothelial growth factor, RGS-5, and hypoxia-inducible factor-1α in the tumor. Although this study supports efficacy of bortezomib against pancreatic carcinoma in vitro, it strongly indicates that bortezomib therapy has a significant tumor-promoting effect in vivo by induction of angiogenesis. The data are in accordance with the complete failure of bortezomib in a phase II trial for this indication. Choosing the right schedule of gemcitabine and bortezomib showed some synergistic effects, but the gain might not be big enough to compensate the potentially detrimental effects. [Mol Cancer Ther 2008;7(11):3624–31]

[1]  S. Post,et al.  Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma. , 2001, Hepato-gastroenterology.

[2]  M. Pirrotta,et al.  Unusual discordant responses in two multiple myeloma patients during bortezomib treatment. , 2008, Onkologie.

[3]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[4]  David R. Jones,et al.  Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. , 2004, The Annals of thoracic surgery.

[5]  Tarik Tihan,et al.  The hypoxic response of tumors is dependent on their microenvironment. , 2003, Cancer cell.

[6]  P. Elliott,et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.

[7]  L. Schwartz,et al.  Phase II trial of bortezomib for patients with advanced renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[9]  C C Travis,et al.  Interspecific scaling of toxicity data. , 1988, Risk analysis : an official publication of the Society for Risk Analysis.

[10]  P. Schaefer,et al.  PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  G. Bergers,et al.  Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. , 2005, Blood.

[12]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[13]  K. Neville,et al.  Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[16]  E. Vokes,et al.  Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Bold,et al.  Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. , 2001, The Journal of surgical research.

[18]  Christopher G Willett,et al.  Locally advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[20]  M. Adachi,et al.  Prognostic significance of angiogenesis in human pancreatic cancer , 1999, British Journal of Cancer.

[21]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[22]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[23]  J. Delcros,et al.  Proteasome inhibitors as therapeutic agents: current and future strategies. , 2003, Current medicinal chemistry.

[24]  C. Travis,et al.  Interspecies extrapolation of pharmacokinetics. , 1990, Journal of theoretical biology.

[25]  P. Elliott,et al.  PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. , 2002, Molecular cancer therapeutics.

[26]  R. Bold,et al.  Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. , 2003, The Journal of surgical research.

[27]  T. Fukuda,et al.  High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma , 2000, Cancer.

[28]  M. Dewhirst.  Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. , 2007, Cancer research.

[29]  J. Adams,et al.  The proteasome: structure, function, and role in the cell. , 2003, Cancer treatment reviews.

[30]  J. Schmidt,et al.  Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma , 2007, Gut.

[31]  P. Elliott,et al.  Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  R. Millikan,et al.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  R. Herbst,et al.  The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  P. Elliott,et al.  Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  R. Perez-soler,et al.  Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells* , 2003, Journal of Biological Chemistry.

[37]  J. Neoptolemos,et al.  PHASE III RANDOMISED COMPARISON OF GEMCITABINE (GEM) WITH GEMCITABINE PLUS CAPECITABINE (GEM-CAP) IN PATIENTS WITH ADVANCED PANCREATIC CANCER , 2005 .

[38]  S. Soignet,et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  C. Logothetis,et al.  Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. , 2003, Molecular cancer therapeutics.

[40]  JB Almond,et al.  The proteasome: a novel target for cancer chemotherapy , 2002, Leukemia.

[41]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Kawakami,et al.  Angiogenesis in pancreatic carcinoma , 2001, Cancer.

[43]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.